BioSpace News Archive

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, announced that Jack Weinstein, a seasoned life science executive with deep financial experience, has been appointed as the Chairman of the Board of Directors.

Boston Children’s Hospital and ElevateBio announced that they have entered into a five-year collaborative agreement to advance cell and gene therapy programs originating out of Boston Children’s Hospital with an introduction to Boston Children’s translational research capabilities.

Carmot Therapeutics, Inc., a clinical-stage biotechnology company applying its proprietary therapeutic platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced that in connection with the recent U.S. FDA approval and commercial launch of Amgen’s LUMAKRAS, Carmot is eligible to receive royalty payments from future sales.

Mosaic ImmunoEngineering Inc., a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced a new preclinical publication available online in the journal Biomaterials that further expand the understanding of the antitumor potency and mechanism of action of the Company’s lead immuno-oncology candidate, MIE-101, a novel Toll-like receptor tri-agonist.

vTv Therapeutics Inc. today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.

Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population

Rigel Pharmaceuticals, Inc. today announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial.

The US Food and Drug Administration (FDA) has granted Fast Track Development (FTD) status for Cend’s investigational drug, CEND-1, for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) in combination with gemcitabine/nab-paclitaxel.

Akoya Biosciences Inc. today announced partnerships with premier microscope providers, Nikon, CrestOptics, and Andor to enable the development of new spatial biology applications, through the recently announced I 2 Network

To support large-scale research and surveillance programs, Thermo Fisher Scientific today introduced the Thermo Scientific SpeciMAX Saliva Collection Kit*.